The invention provides stem cell-derived apoptotic extracellular vesicles (ApoEVs) with an iron homeostasis regulation effect and application of the stem cell-derived apoptotic extracellular vesicles in preparation of a medicine for treating iron-deficiency anemia, and belongs to the technical field of biological medicines. The ApoEVs is an outer vesicle separated from apoptotic cells derived from human periodontal ligament stem cells, and can effectively recover the iron level in low-iron cells induced by DFOM, up-regulate the expression of iron storageprotein and regulate the level of iron export protein, thereby improving the iron homeostasis of the cells. Meanwhile, the ApoEVs have good biocompatibility and safety, and a new strategy is provided for treatment of iron-deficiency anemia.
A method of testing the concentration of molybdatecorrosion inhibitor in water of a central heating system is disclosed. The method comprises testing the iron concentration using an immersion test pad and testing the molybdate concentration using an immersion test pad. In the evaluation of the immersion test pad testing the molybdate concentration, the level of iron evaluated is taken into account. This results in more accurate and reliable results than achieved with known immersion tests.
The invention relates to a pharmaceutical composition comprising iron (III) polymaltose complex and an active ingredient selected from calcium folinate pentahydrate, vitamin C or a combination of both, wherein the active ingredients are stored separately in a container consisting of a cylindrical bottle and a storage closure, wherein the iron (III) polymaltose is stored in the form of an oral solution in the bottle and the calcium folinate pentahydrate or vitamin C or a combination thereof are stored separately in a sealed manner in solid form in the storage closure. The container is properly configured to allow the two substances to be mixed just before use, forming a single-dose oral solution. The pharmaceutical composition helps to increase blood iron levels and treat anemia in pregnancy and lactation.
The present disclosure relates to a circular RNA molecule having an iron responsive element (IRE) comprising the sequence of SEQ ID NO: 1, SEQ ID NO:4, or a portion thereof sufficient to allow for binding to an iron responsive protein. Also disclosed are DNA constructs encoding the circular RNA molecule, host cells that include the circular RNA molecule, pharmaceutical compositions comprising the circular RNA molecule or DNA constructs encoding the circular RNA molecule, and methods of treating a disease or disorder mediated by iron overload.